Chapter stringclasses 62
values | Section stringclasses 571
values | Subsection stringclasses 845
values | Subsubsection stringclasses 240
values | Text stringlengths 1 4.01k |
|---|---|---|---|---|
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | treatment issues, 1103–1107 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Z |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Zoledronic acid |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | aromatase inhibitors, 757 bone metastases and, 1068 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | characteristics of, 685–687, 688t, 689 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | osteoporosis, 719, 1068 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | ovarian ablation, 630, 631 |
Cost and Cost Effectiveness | PALLIATIVE AND END OF LIFE CARE | null | null | Zuska’s disease, 85 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.